On October 1, Alnylam Pharmaceuticals fell 5.13% in regular trading, trading at $234.2 per share with turnover of $152 million. The decline comes amid a wave of investment bank price target reductions that have continued to weigh on market sentiment.

On the news front, several major investment banks have recently cut their price targets on the stock. JPMorgan maintained its overweight rating but lowered its target from $375 to $369. Cantor Fitzgerald reiterated a neutral rating with a $325 target. RBC Capital Markets slashed its target sharply to $350 from $445 while keeping an outperform rating, and BofA Securities reduced its target from $460 to $410 while maintaining a buy rating. The consecutive downgrades reflect growing caution among analysts regarding the company's growth trajectory.

The cautious tone follows the company's Q2 earnings release in late July, when Alnylam beat adjusted EPS estimates at $1.84 per share but missed revenue expectations at $1.291 billion. The company also lowered its full-year net product revenue guidance to $4.70-5.10 billion from a prior range of $4.90-5.30 billion, citing normalizing second-line Amvuttra demand in the ATTR-CM market.

Alnylam Pharmaceuticals is a biopharmaceutical company specializing in RNA interference therapeutics, with core products spanning rare diseases and cardiovascular indications.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)